Bioxodes announces the initiation of a double blind, placebo controlled, single ascending dose phase I trial
Bioxodes announces on October, 15 obtaining the authorization to launch phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers
Ir-CPI is a potential best-in-class antithrombotic drug having an innovative mechanism of action (coagulation factors XIIa/XIa inhibition) to reduce bleeding risk in acute cardiovascular settings.
Bioxodes, a clinical stage biotech company, announces the initiation of a double blind, placebo controlled, single ascending dose phase I trial with its candidate, Ir-CPI, in healthy male volunteers.
The objectives of this phase I study are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the drug candidate, Ir-CPI. The clinical trial has already been launched in Belgium, early October.
“The launch of this phase I clinical trial with Ir-CPI is a major milestone for the recognition by the regulatory authorities of the quality of the data generated by our team,” said Edmond Godfroid, CEO of Bioxodes. “We are eager to learn more about Ir-CPI in the clinic after obtaining very encouraging preclinical activity and safety profile of our lead product, soon to be published in the renowned journal JACC.”
“This publication clearly validates the scientific results of Bioxodes, emphasizing their relevancy and scientific interest. It represents a tremendous support for the ongoing clinical studies” said the KOL Prof. Cédric Hermans, Head of Haemostasis and Thrombosis at St-Luc University Hospital, Brussels.
If you want to know more about the company and its clinical development, contact Edmond Godfroid, CEO via info@bioxodes.com.
The launch is a major milestone for the recognition by the regulatory authorities of the quality of the data generated by our team
